

ENCALS statement on edaravone, Conflict of Interest (COI) - July 2017

Name	Affiliation	COI
Belgium		
Philip Van Damme	KU Leuven – University of Leuven, Department of Neurosciences, Experimental Neurology; VIB Center for Brain & Disease Research; University Hospitals Leuven, Department of Neurology, Leuven, Belgium	received consulting fees from Mitsubishi, Cytokinetics, Biogen Idec
Denmark		
Kirsten Svenstrup	Department of Neurology, Bispebjerg Hospital, Copenhagen, Denmark	no disclosures
Merete Karlsborg	Department of Neurology, Bispebjerg Hospital, Copenhagen, Denmark	no disclosures
Finland		
Hannu Laaksovirta	Helsinki University Central Hospital, Finland	No disclosures
France		
Francois Salachas	Hôpital de la Salpêtrière, Paris, France	no disclosures
Philippe Corcia	Centre de compétence SLA-fédération Tours-Limoges, CHU de Tours, France	Investigator for clinical trials led by Cytokinetics, Consulting fees from Roche
Philippe Couratier	Centre de compétence SLA-fédération Tours-Limoges, CHU de Limoges, France	no disclosures
Claude Desnuelle	Hôpital Pasteur 2 – CHU de Nice, France	consultant EFFIK SA France, Sanofi –Genzyme Co, NanoMedSyn
Germany		
Julian Grosskreutz	Hans-Berger Department of Neurology, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany	consulted for Biogen
Thomas Meyer	ALS Outpatient Department, Charité - Universitätsmedizin Berlin, Germany	consulted for Cytokinetics, GSK and Desitin Arzneimittel GmbH, founder of the internet platform Ambulanzpartner and co-owner of Ambulanzpartner Soziotechnologie GmbH

Susanne Petri	Department of Neurology, Hannover Medical School, Hannover, Germany	consulted for Cytokinetics, Investigator for clinical trials led by Cytokinetics, Orion Pharma, Biogen Idec, GlaxoSmithKline; speaking honoraria from Teva
Jan Christoph Koch	Department of Neurology, University Medicine Göttingen, Göttingen, Germany	Co-PI of IIT ROCK-ALS
Patrick Weydt	Department of Neurodegenerative Diseases and Gerontopsychiatry, Bonn University, Germany	no disclosures
Joachim Wolf	Department of Neurology, Mannheim, Diakonissenkrankenhaus, Germany	no disclosures
Torsten Grehl	Alfried Krupp Krankenhaus, Rüttenscheid, Germany	no disclosures
Albert Ludolph	Department of Neurology, University of Ulm, Germany	on an advisory board of Biogen, Treeway, Hoffmann-La Roche, has signed contracts for clinical Studies with AB Science, Biogen Idec, Cytokinetics, GSK, Orion Pharam, Novartis, TauRx Therapeutics Ltd. and TEVA Pharmaceuticals, consulted for Mitsubishi, Orion Pharma, Novartis, Teva
Ireland		
Orla Hardiman	Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland	consulted for Mitsubishi and for Treeway
Italy		
Adriano Chio	Rita Levi Montalcini' Department of Neuroscience, ALS Center, University of Torino, Torino, Italy	served on an advisory panel on MITOS and KING'S for Mitsubishi-Tanabe, consultant without compensato to Treeway, consultant for Biogen Idec and Italfarmaco
Vincenzo Silani	Department of Neurology-Stroke Unit and Laboratory of Neuroscience, Department of Pathophysiology and Transplantation, Center for Neurotechnology and Brain Therapeutics, Università degli Studi di Milano, IRCCS Istituto Auxologico Italiano, Piazzale Brescia no. 20, 20149 Milan, Italy	received consulting fees from Mitsubishi and Cytokinetics

Netherlands		
Leonard H van den Berg	Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands	consultant without compensation to Treeway, LHvdb declares personal fees from Baxalta, and is a member of the Scientific Advisory Boards for Biogen Idec, Cytokinetics and Orion
Anneke van der Kooi	Department of Neurology, Academic Medical Centre, University of Amsterdam Center, The Netherlands.	received research grant from Behring for investigator initiated study
Norway		
Trygve Holmøy	Kershus Universitetssykehus Lørenskog, Norway	Received consulting fees from Biogen, Merck, Genzyme and run studies without compensation for Merck and Biogen, not related to ALS
Grethe Kleveland	Avdeling for nevrologi og klinisk nevrofysiologi, Sykehuset Innlandet, Lillehammer, Norway	no disclosures
Ole-Bjørn Tysnes	Haukeland universitetssjukehus, Bergen	no disclosures
Poland		
Magdalena Kuzma-Kozakiewicz	Department of Neurology, Medical University of Warsaw, Żwirki i Wigury 61, 02-091, Poland	no disclosures
Portugal		
Mamede de Carvalho	Institute of Physiology-Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal. Department of Neurosciences And Mental Health, H Santa Maria-CHLN, Portugal	Received consulting fees from Biogen, Merck Idec, Kedrion and Cytokinetics
Scotland		
Siddharthan Chandran	University of Edinburgh, Scotland, UK	no disclosures
Slovenia		
Blaz Koritnik	Institute of Clinical Neurophysiology, University Medical Centre Ljubljana, Zaloska 7, SI-1000 Ljubljana, Slovenia	no disclosures
Spain		

Jesus Mora Pardina	Madrid, Spain	consulted for AB-Science
Mónica Povedano Panades	Neurology department Hospital Universitario de Bellvitge-IDIBELL, Barcelona, Spain	no disclosures
Sweden		
Peter M. Andersen	Department of Pharmacology and Clinical Neuroscience, Umeå University, SE-901 85 Umeå, Sweden	received consulting fees from Biogen Idec and Orphazyme ApS on matters concerning clinical trials and ALS
Bernardo Mitre Ropero	Sahlgrenska Universitetssjukhuset, Gothenburg, Sweden	no disclosures
Ingela Nygren	Uppsala University, Sweden	no disclosures
Gert Staaf	Lund University, Sweden	no disclosures
Caroline Ingre	Karolinska Instituted, Stockholm, Sweden	no disclosures
Olof Danielsson	Department of Neurology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden	no disclosures
Switzerland		
Markus Weber	Neuromuscular Diseases Center/ALS Clinic, Kantonsspital St. Gallen, St.Gallen, Switzerland	received consulting fees from Mitsubishi, Biogen Idec, Merz Parma Schweiz, consultant without compensation to Treeway
United Kingdom		
Pamela Shaw	Sheffield Institute for Translational Neuroscience, University of Sheffield, UK	Consultant without compensation for Treeway and is a member of scientific advisory boards for Biogen, and Orion.
Christopher McDermott	Sheffield Institute for Translational Neuroscience, University of Sheffield, UK	Consulted for OrionPharma; Investigator for studies run by Biogen Idec, cytokinetics
Kevin Talbot	Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK	no disclosures
Ammar Al-Chalabi	Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, King's College London, London, UK	Consulted for Mitsubishi-Tanabe Pharma, Cytokinetics, OrionPharma, Chronos Therapeutics, Treeway, GSK, Lilly, Biogen Idec; Chief Investigator for clinical trials run by Cytokinetics, OrionPharma; speaking honoraria from Cytokinetics Inc and Lilly